Compare VRAX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | XBIO |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 5.9M |
| IPO Year | 2022 | N/A |
| Metric | VRAX | XBIO |
|---|---|---|
| Price | $0.36 | $2.16 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 15.5M | 35.4K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,986.00 | ★ $2,858,935.00 |
| Revenue This Year | $217,274.83 | $1.99 |
| Revenue Next Year | N/A | $20.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.30 |
| 52 Week Low | $0.31 | $1.90 |
| 52 Week High | $3.20 | $13.93 |
| Indicator | VRAX | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 41.11 |
| Support Level | $0.31 | $1.95 |
| Resistance Level | $0.43 | $2.29 |
| Average True Range (ATR) | 0.04 | 0.14 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 25.29 | 41.27 |
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.